GO
Loading...

Medicine

More

  • Merck And Big Pharma: Both Getting A Stock "Booster" Shot? Wednesday, 19 Mar 2008 | 11:14 AM ET
    Gardasil

    Merck this morning announced that it has filed for Food and Drug Administration approval of its blockbuster cervical cancer vaccine, Gardasil, for women 27-45 years old. Right now it's approved for females 9-26.

  • Amgen And Its Rather Anemic Stock Performance Tuesday, 18 Mar 2008 | 11:54 AM ET

    Shares of Amgen closed just above 43 bucks yesterday. That's more than a five-year low. And they're falling even lower in early trading this morning. Today the company is making its first investor presentation since last week's FDA advisory committee vote to restrict usage of Amgen's anemia drugs on cancer patients.

  • Genentech: Top O The Mornin' This St. Patty's Day Monday, 17 Mar 2008 | 10:03 AM ET

    This St. Patrick's Day morning several analysts are out with their official takes on Genentech's investor meeting last Friday and of the half dozen or so I've seen so far, I'd say the reaction is definitely mixed. I also wanted to throw in a few more notable quotables from CEO Art Levinson at the Friday presentation.

  • Genentech And The Bear Stearns Bailout Friday, 14 Mar 2008 | 3:14 PM ET

    So guess which analyst happened to be selected first to query Genentech management at the start of the Q and A portion of the biotech company's analyst meeting? Yep. Mark Schoenebaum from Bear Stearns.

  • Amgen, JNJ Get Somewhat Mixed Message From FDA Panel Thursday, 13 Mar 2008 | 4:32 PM ET

    Amgen, the world's biggest biotech company in terms of sales (Genentech dwarfs Amgen in market cap: $86 billion vs. $51 billion) and Dow component Johnson & Johnson avoided a worst-case scenario this afternoon.

  • Genentech In 2007: Stock Ends Down, Exec Comp Goes Up Thursday, 13 Mar 2008 | 12:26 PM ET

    Last year Genentech shares traded as high as nearly 88 dollars, but ended 2007 around 67 bucks. But according to the company's new proxy statement all of Genentech's top-tier executives saw their total compensation go up.

  • Amgen's Anemia Drug Showdown Wednesday, 12 Mar 2008 | 4:26 PM ET

    Ahead of the big FDA Advisory Committee meeting tomorrow, Amgen held a quick conference call with some reporters this afternoon. The outside panel of experts will be deciding whether to recommend putting more restrictions on the use of the blockbuster drugs used to fight anemia in cancer patients getting chemo. For Johnson and Johnson and especially Amgen, the stakes are high.

  • A SPA Break For Dendreon Wednesday, 12 Mar 2008 | 10:08 AM ET

    Everyone's favorite small-cap biotech put out a press release this morning, announcing that the Food and Drug Administration has agreed to change the Special Protocol Assessment (SPA) for Dendreon's Provenge.

  • Amgen, Johnson & Johnson & The FDA Tuesday, 11 Mar 2008 | 1:23 PM ET

    Shares of biotech giant Amgen fell as low as $43.14 (a new bottom) this morning after the briefing documents for Thursday's Food and Drug Administration Advisory Committee meeting were posted on the agency's website.

  • One Giant Leap for MannKind Monday, 10 Mar 2008 | 5:11 PM ET

    Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.

  • Amgen And Genentech: A Big Biotech Double Play Monday, 10 Mar 2008 | 10:50 AM ET
    AMGEN

    This is a big week for the world's top-two biotechnology companies and their investors. Amgen goes before an FDA Advisory Committee Thursday about the side effects of its bread-and-butter franchise Aranesp.

  • First, Pfizer gave up on its inhaled insulin Exubera, then NovoNordisk threw in the towel and now it looks like Lilly is going to bow out. Alkermes, which is working on a palm-sized product called, "AIR Insulin," put out a press release today saying it expects its partner on the device, Lilly, to decide next week that it will exit the deal. ALKS shares hit a new low on the news.

  • Analyst: Pfizer Should Buy Amgen or Wyeth Friday, 7 Mar 2008 | 10:48 AM ET

    I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...

  • Pfizer Analyst Day: The Analysts React Thursday, 6 Mar 2008 | 10:16 AM ET

    Pfizer held its analyst day yesterday and the stock closed at a new multi-year low. This morning the shares are under a little bit of pressure again as analyst reaction to the event pours in.

  • FDA Turns Over Dendreon Documents Wednesday, 5 Mar 2008 | 3:49 PM ET

    When I got back from the Pfizer analyst meeting in New York City this afternoon, I found a treasure trove of PDF documents in one of my inboxes from a couple of Dendreon/Provenge proponents from their Freedom of Information Act request to the Food and Drug Administration...

  • Pfizer CEO: We're Ready For Generic Lipitor Wednesday, 5 Mar 2008 | 2:25 PM ET

    I'm in the press room at the midtown Manhattan hotel where Pfizer is holding its analyst meeting. There's just over half a dozen reporters here and we're nearly outnumbered by PR folks. As one of them remarked, the press turnout for an event like this just isn't what it used to be...

  • Baxter, Biogen Idec & Elan Subjects of Broken Embargoes Wednesday, 5 Mar 2008 | 8:15 AM ET

    Embargoes imposed by scientific groups and medical journals will once again be put to the test over the next couple of months.

  • Pfizer Not Getting The Love Before Analyst Meeting Tuesday, 4 Mar 2008 | 3:38 PM ET

    The day before Pfizer's analyst meeting tomorrow investors are not showing much love for the beaten-down Dow component. PFE's trading in the early going today at its lowest level since December 2005.

  • Drug Money Still A "Healthy Flow" To Democrats Monday, 3 Mar 2008 | 9:29 AM ET

    On the eve of the make-or-break Texas-Ohio primaries for Sen. Hillary Clinton, she remains in first place in at least one "poll." The Center for Responsive Politics has updated its list of top pharmaceuticals/health products-industry money recipients based on the most recent campaign finance reports and the former First Lady edges out Sen. Barack Obama...

  • Lechleiter Likes Lilly--A Lot Thursday, 28 Feb 2008 | 9:50 AM ET

    When Schering-Plough Chairman and CEO Fred Hassan recently decided to buy another $2 million worth of SGP shares in the wake of the Vytorin study takedown, the company put out a press release.